Filing Details
- Accession Number:
- 0001127602-22-025018
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-07 16:06:49
- Reporting Period:
- 2022-11-03
- Accepted Time:
- 2022-11-07 16:06:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
310158 | Merck & Co. Inc. | MRK | Pharmaceutical Preparations (2834) | 221918501 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1181175 | C Kenneth Frazier | Merck &Amp; Co., Inc. 126 E. Lincoln Avenue Rahway NJ 07065 | Executive Chair | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-11-03 | 235,000 | $0.00 | 935,653 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-11-03 | 214,617 | $98.68 | 721,036 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-11-03 | 20,383 | $99.09 | 700,653 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2022-11-04 | 235,000 | $0.00 | 935,653 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-11-04 | 200,190 | $98.53 | 735,463 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-11-04 | 34,810 | $99.08 | 700,653 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2022-11-03 | 235,000 | $0.00 | 235,000 | $53.06 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2022-11-04 | 235,000 | $0.00 | 235,000 | $53.06 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
470,769 | 2017-05-10 | 2026-05-09 | No | 4 | M | Direct |
235,769 | 2017-05-10 | 2026-05-09 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock - 401(K) Plan | 4,481 | Indirect | By 401(k) |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- Holdings include shares acquired in dividend reinvestment transactions.
- Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
- The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.